<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03019471</url>
  </required_header>
  <id_info>
    <org_study_id>NL55080.068.15</org_study_id>
    <nct_id>NCT03019471</nct_id>
  </id_info>
  <brief_title>Non Invasive Cancer Test (NICT): a Proof of Principle Study.</brief_title>
  <acronym>NICT-NIPT-CA</acronym>
  <official_title>Non Invasive Cancer Test (NICT): a Proof of Principle Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim to collect tumor DNA out of blood of cancer patients. If this is
      successful this could lead to the development of a cancer test in blood in the future, which
      is less invasive than current diagnostic methods.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>ctDNA</measure>
    <time_frame>One year</time_frame>
    <description>Demonstrate the presence or absence of ctDNA in patients plasma. Examine if there us a sufficient concentration of ctDNA in the plasma to reliably diagnose cancer and determine the CNV</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Neoplasmata</condition>
  <arm_group>
    <arm_group_label>Lung cancer</arm_group_label>
    <description>Isolate Tumor DNA from the patients blood.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Breast cancer</arm_group_label>
    <description>Isolate Tumor DNA from the patients blood.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Colorectal cancer</arm_group_label>
    <description>Isolate Tumor DNA from the patients blood.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glioma</arm_group_label>
    <description>Isolate Tumor DNA from the patients blood.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Isolation of tumor DNA</intervention_name>
    <arm_group_label>Lung cancer</arm_group_label>
    <arm_group_label>Breast cancer</arm_group_label>
    <arm_group_label>Colorectal cancer</arm_group_label>
    <arm_group_label>Glioma</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        1. Patients with newly diagnosed local or metastatic breast cancer, colorectal cancer,
             non-small cell lung cancer and anaplastic glioblastoma, before start of radiation
             therapy, chemoradiation or chemotherapy.

          2. Patients age &gt; 18 years, willing and able to comply with the protocol as judged by the
             investigator with a signed informed consent
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with newly diagnosed local or metastatic breast cancer, colorectal cancer,
             non-small cell lung cancer and anaplastic glioblastoma, before start of radiation
             therapy, chemoradiation or chemotherapy.

          2. Patients age &gt; 18 years, willing and able to comply with the protocol as judged by the
             investigator with a signed informed consent

        Exclusion Criteria:

          1. Patients with a history of malignant disease other than the disease under study, with
             an exception for adequately treated squamous cell carcinoma of the skin, basal cell
             carcinoma of the skin and in situ cervix carcinoma.

          2. Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine C. De Die-Smulders, Prof. dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Geneticist in MUMC+</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Merryn M. Macville, Dr.</last_name>
    <phone>+31-43-3875843</phone>
    <email>m.macville@mumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Job J. Verdonschot, Drs.</last_name>
    <phone_ext>+31-43-3877093</phone_ext>
    <email>job-verdonschot@mumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6229 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M. Eijck-Vievermans</last_name>
      <phone>+313876447</phone>
      <email>margo.vievermans@mumc.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2017</study_first_submitted>
  <study_first_submitted_qc>January 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2017</study_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

